ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


Silence Therapeutics.
93 announcements.
Time Ticker Company Announcement
15:19 SLN Silence Therapeutics
Additional Listing
16:46 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Interim results for six months ended 30 June 2019
08:28 SLN Silence Therapeutics
Holding(s) in Company
10:14 SLN Silence Therapeutics
Additional Listing
15:15 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Notice of Results and R&D day
07:00 SLN Silence Therapeutics
Additional Listing
16:27 SLN Silence Therapeutics
Additional Listing
13:38 SLN Silence Therapeutics
Additional Listing
12:41 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Silence Therapeutics appoints J�rgen Wittendorff
16:22 SLN Silence Therapeutics
Holding(s) in Company
08:19 SLN Silence Therapeutics
Holding(s) in Company
17:30 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Board Appointment
13:33 SLN Silence Therapeutics
Holding(s) in Company
12:26 SLN Silence Therapeutics
Holding(s) in Company
08:43 SLN Silence Therapeutics
Holding(s) in Company
11:27 SLN Silence Therapeutics
Additional Listing
16:35 SLN Silence Therapeutics
Price Monitoring Extension
15:13 SLN Silence Therapeutics
Additional Listing
11:45 SLN Silence Therapeutics
Silence collaboration with Mallinckrodt
11:46 SLN Silence Therapeutics
Mallinckrodt to make equity investment in Silence
11:46 SLN Silence Therapeutics
Holding(s) in Company
14:06 SLN Silence Therapeutics
Additional Listing
12:09 SLN Silence Therapeutics
Result of AGM
13:20 SLN Silence Therapeutics
Holding(s) in Company
14:36 SLN Silence Therapeutics
Holding(s) in Company
13:36 SLN Silence Therapeutics
Holding(s) in Company
13:00 SLN Silence Therapeutics
Holding(s) in Company
09:16 SLN Silence Therapeutics
Holding(s) in Company
16:37 SLN Silence Therapeutics
Holding(s) in Company
13:37 SLN Silence Therapeutics
Holding(s) in Company
12:28 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Collaboration with Genomics England
16:46 SLN Silence Therapeutics
Additional Listing
15:00 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Additional Listing
16:55 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Silence Therapeutics Announces Board Changes
07:00 SLN Silence Therapeutics
Silence Therapeutics Publication of Annual Report
07:00 SLN Silence Therapeutics
Appointment of Chief Financial Officer
11:00 SLN Silence Therapeutics
Silence Therapeutics Announces Board Change
07:00 SLN Silence Therapeutics
Silence Therapeutics appoints Head of R&D and CMO
09:09 SLN Silence Therapeutics
Holding(s) in Company
07:00 SLN Silence Therapeutics
Silence Therapeutics submits CTA for SLN124
07:00 SLN Silence Therapeutics
2018 Preliminary Results
07:00 SLN Silence Therapeutics
Silence to Present at Cowen Healthcare Conference
07:00 SLN Silence Therapeutics
Notice of Results
15:35 SLN Silence Therapeutics
Holding(s) in Company
17:24 SLN Silence Therapeutics
Holding(s) in Company
16:40 SLN Silence Therapeutics
Second Price Monitoring Extn
16:35 SLN Silence Therapeutics
Price Monitoring Extension
07:00 SLN Silence Therapeutics
SLN124 granted Orphan Drug Designation by EMA
07:00 SLN Silence Therapeutics
Departure of Chief Financial Officer
07:00 SLN Silence Therapeutics
Silence Therapeutics advances next RNAi medicine
16:35 SLN Silence Therapeutics
Price Monitoring Extension
07:00 SLN Silence Therapeutics
Settlement and License Agreement with Alnylam
17:12 SLN Silence Therapeutics
Results of Placing
10:14 SLN Silence Therapeutics
PTAB Upholds Silence Patent
07:00 SLN Silence Therapeutics
New divisional patent and injunction application
14:16 SLN Silence Therapeutics
Holding(s) in Company
07:00 SLN Silence Therapeutics
Silence to Present at Healthcare Conference
14:19 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Interim results for six months ended 30 June 2018
10:53 SLN Silence Therapeutics
Holding(s) in Company
10:46 SLN Silence Therapeutics
Holding(s) in Company
07:00 SLN Silence Therapeutics
Notice of Results
09:30 SLN Silence Therapeutics
Silence Therapeutics Announces Board Change
07:00 SLN Silence Therapeutics
Litigation: patisiran EU MA imminent
15:00 SLN Silence Therapeutics
Director/PDMR Shareholding
13:00 SLN Silence Therapeutics
Appoints David Horn Solomon as CEO
07:00 SLN Silence Therapeutics
Licensee Quark Pharmaceuticals Patient Dosed Ph 3
07:00 SLN Silence Therapeutics
Silence Strengthens Board and Leadership Team
16:35 SLN Silence Therapeutics
Price Monitoring Extension
07:00 SLN Silence Therapeutics
Presents Data on Lead Programme SLN124 at EHA
10:15 SLN Silence Therapeutics
Silence Therapeutics Announces Leadership Change
07:00 SLN Silence Therapeutics
Post year end business update
07:00 SLN Silence Therapeutics
Key European patent granted
11:48 SLN Silence Therapeutics
Holding(s) in Company
08:58 SLN Silence Therapeutics
Holding(s) in Company
11:38 SLN Silence Therapeutics
Grant of share options and restricted stock units
14:27 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Notice of Results
15:40 SLN Silence Therapeutics
Holding(s) in Company
07:00 SLN Silence Therapeutics
Silence to present at Cowen Health Care Conference
07:00 SLN Silence Therapeutics
Preliminary results year ended 31 December 2017
07:00 SLN Silence Therapeutics
Notice of AGM
07:00 SLN Silence Therapeutics
Silence to Present at Scientific Conferences
07:00 SLN Silence Therapeutics
Litigation Update (Portugal and US)
17:00 SLN Silence Therapeutics
Additional Listing
07:00 SLN Silence Therapeutics
Results of AGM